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Abstract
Mucus is a porous biopolymer matrix that coats all wet epithelia in the human body and serves as
the first line of defense against many pathogenic bacteria and viruses. However, under certain
conditions viruses are able to penetrate this infection barrier, which compromises the protective
function of native mucus. Here, we find that isolated porcine gastric mucin polymers, key
structural components of native mucus, can protect an underlying cell layer from infection by
small viruses such as human papillomavirus (HPV), Merkel cell polyomavirus (MCV), or a strain
of influenza A virus. Single particle analysis of virus mobility inside the mucin barrier reveals that
this shielding effect is in part based on a retardation of virus diffusion inside the biopolymer
matrix. Our findings suggest that purified mucins may be used as a broad-range antiviral
supplement to personal hygiene products, baby formula or lubricants to support our immune
system.
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Introduction
Viral infections constitute a main class of pathogen-induced diseases. However, because of
high mutation rates and the relatively high degree of dissimilarity between different types of
viruses, it is difficult to develop broad-spectrum antiviral agents. Therefore, in many cases
we rely on our innate immune system to repel viral infections, especially when vaccinations
are unavailable or inefficient. A crucial part of the innate immune system is constituted by
mucus. Mucus is a biopolymer-based hydrogel that lines all moist epithelia of humans and
animals. One important function of mucus is to provide a physical barrier that prevents
microbial pathogens from reaching the underlying epithelial cells 1.
The exact mechanisms by which mucus prevents viral infections remain elusive. The
identification of critical components of native mucus that provide antiviral activity might
bear an enormous potential for the discovery of new antiviral substances. Native cervical
mucus can trap various types of particles, and under certain conditions even particles that are
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smaller than the mesh size of the mucus matrix (~340 nm) 2, including the herpes simplex
virus-1 (HSV-1, ~180 nm) and human immunodeficiency virus-1 (HIV-1, ~120 nm) 2–3.
This effect is often referred to as ‘mucoadhesion’ and is based on binding interactions
between the mucin biopolymers and the diffusing particles 4. The major gel-forming units of
mucus are mucins, large glycoproteins with molecular weights up to hundreds of kDa that
carry many carbohydrate groups including N-acetylgalactosamine, fucose, galactose and
sialic acid 1b. Those carbohydrates can establish up to 70 % of the mucin mass. It appears
that mucins might play a major role in the phenomenon of mucoadhesion. Indeed, isolated
human salivary mucins directly interact with HIV-1 5 and have also been suggested to
reduce HSV-1 infectivity 6. Moreover, purified human breast milk mucins can block
poxvirus infection 7, and isolated gastrointestinal mucins inhibit rotaviruses 8 and
noroviruses 9.
Given the wide range of viruses that can be inhibited by different isolated mucins, it is
possible that mucins might be able to act as broad-spectrum antiviral agents. If this is true,
then mucins would be an interesting supplement for hygiene or health products, or lubricants
to support the natural immune system. Obtaining large quantities of mucins from human
sources such as breast milk is difficult, though. The mucosa of porcine stomachs, from
which mucins can be isolated in bulk, could provide an attractive alternative source for
mucin glycoproteins. Indeed, porcine gastric mucins have previously been used as a
component of artificial saliva for the treatment of subjects suffering from salivary
insufficiency (xerostomia) 10. The antiviral properties of porcine gastric mucins, however,
have not been tested yet.
Here, we explore the antiviral activity of porcine gastric mucins. We demonstrate that a
solution containing purified porcine gastric mucins 11 can efficiently prevent infection of
epithelial cells by a broad range of small mucosotropic viruses such as human papilloma
virus type 16 (HPV- 16), Merkel cell polyoma-virus (MCV) and a strain of influenza A
virus. HPV-16 and MCV have comparable diameters of around 50 nm 12, whereas a typical
diameter for an influenza virion is around 100 nm 13. These sizes are all significantly
smaller than the mesh size of native mucus gels 2. We find that reconstituted mucins do not
compromise the viability of human cervical cell lines or human lung cell lines. Moreover,
our results suggest that the ability of mucins to block viral infections is mainly due to a
retardation of virus diffusion within the mucin solution.
Materials and Methods
Proteins and hydrogel reconstitution
Bovine serum albumin (BSA), matrigel (= basal lamina, a subtype of the extracellular
matrix, in this article referred to as ‘ECM’) and dextran (MW: 2 MDa) were obtained from
Sigma-Aldrich (St. Louis, MO), commercial mucins were purchased from Sigma Aldrich
and from NBS Biologicals (Huntingdon, UK). The complex ECM Matrigel has been
purified from the basal membrane of the Engelbreth-Holm-Swarm sarcoma of mice and is
widely used as a model system for native ECM. A 1 % (w/v) stock solution of ECM was
thawed on ice and diluted with Dulbecco’s Modified Eagle Medium (DMEM, Invitrogen,
Carlsbad, CA) where necessary. Once applied to cells, it was incubated for 30 min at 37 °C
to induce gelation. Porcine gastric mucins were purified from scrapings of fresh pig
stomachs essentially as described in 11a, with the exception that the cesium chloride density
gradient ultracentrifugation was omitted.
To determine the molecular composition of our mucin preparation in more detail, we
analyzed its content at the “Harvard Microchemistry & Proteomics Analysis Facility” by
microcapillary reverse-phase HPLC nano-electrospray tandem mass spectrometry on a
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Thermo LTQ-Orbitrap mass spectrometer. This instrument is capable of acquiring individual
sequencing spectra at high sensitivity (<< 1 femtomol) for multiple peptides in the
chromatographic run. The spectra are then correlated with known sequences using the
algorithm Sequest 14.
The analysis showed that our mucin preparation contains the following mucins: MUC5AC,
MUC2, MUC5B and MUC6. As expected for the stomach mucosa, MUC5AC seems to be
the major component of our purification. Other proteins within our mucin preparation
include histones, actin, and albumin. Yet, as this mass spec technique is not suitable to
determine exact protein concentrations, we can currently not establish the relative
concentrations of all those proteins.
For reconstitution, lyophilized mucins were hydrated overnight at 4 °C in distilled water.
The homogeneous mucin solutions were buffered to the desired pH with acetate buffer
calibrated to pH 3 or HEPES buffer calibrated to pH 7. The final buffer concentration in the
mucin solution was 20 mM and the ionic strength was adjusted to 20 mM with NaCl. BSA,
dextran and commercial mucins were treated the same way as our purified mucins and
hydrated in either pH 7 HEPES buffer containing 20 mM NaCl, or in PBS.
Virus particles
HPV-16 and MCV reporter vectors (pseudoviruses) carrying GFP reporter plasmids and
fluorescently labeled virus-like particles (VLPs) were generated according to previously-
reported methods 15. In brief, 293T cells were co-transfected with expression constructs
encoding the capsid genes with or without a reporter plasmid encoding GFP. Plasmids used
in this work are available through Addgene.org and detailed protocols are posted at <http://
home.ccr.cancer.gov/LCO/>. The influenza virus used here is the A/WSN/1933 (H1N1)
strain, which is a commonly used influenza lab strain. For this study, the virus has been
modified such that the PB1 segment carries the green fluorescent protein (GFP) in place of
the PB1 coding sequence, as described in 16. As a consequence, these influenza viruses are
only able to replicate in engineered cell lines that express the PB1 protein.
HPV-16 VLPs were conjugated to Alexa Fluor 488 according to Alexa Fluor 488 Protein
Labeling Kit (Invitrogen #A10235) instructions. Clarified cell lysate containing VLPs was
diluted with water to a total protein concentration of 3 mg/ml, adjusted to 0.1 M sodium
bicarbonate and added to a vial of Alexa Fluor 488 reactive dye provided with the kit. The
conjugated VLPs were adjusted to neutral pH with sodium phosphate and then purified over
an Optiprep gradient. Infectivity monitoring using an encapsidated Gaussia Luciferase
plasmid indicated no detectable alteration of the particle-to-infectivity-ratio of Alexa Fluor
488 conjugated VLPs, indicating that the dye conjugation reaction did not have a major
impact on capsid protein function 17.
Cell culture
Human cervical cells (HeLa) were cultured in DMEM (Invitrogen, Carlsbad, CA)
supplemented with L-glutamine, 10% fetal bovine serum (FBS), 4.5 g/L glucose, and 25 U/
mL penicillin, 25 µg/mL streptomycin at 37 °C in a humidified atmosphere at 5 % CO2. The
human alveolar epithelial cell line A549 was cultured in RPMI medium (Invitrogen,
Carlsbad, CA) supplemented with L-glutamine, 5 % FBS, 4.5 g/L glucose, and 25 U/mL
penicillin, 25 µg/mL streptomycin at 37 °C in a humidified atmosphere at 5 % CO2. As an
infection target for the influenza virus, a variant of Madin-Darby canine kidney cells,
MDCK-SIAT1-CMV-PB1, was used. These highly adherent epithelial cells have been
modified by lentiviral transduction to constitutively express the PB1 protein under a CMV
promoter to allow the modified influenza viruses used in this study to efficiently replicate
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inside these cells 16. MDCK cells were cultured in DMEM (Invitrogen, Carlsbad, CA)
supplemented with L-glutamine, 10% fetal bovine serum (FBS), 4.5 g/L glucose, and 25 U/
mL penicillin, 25 µg/mL streptomycin at 37 °C in a humidified atmosphere at 5 % CO2. Cell
counts were performed using a hemocytometer.
In vitro infection assay
For in vitro infection, 5×104 HeLa cells, 7.5×103 A549 cells, or 3×104 MDCK-SIAT1-
CMV-PB1 cells were seeded into each well of a 96-well microtiter plate (BD Biosciences,
San Jose, CA) and allowed to adhere overnight. For MDCK-SIAT1-CMV-PB1 cells, three
hours prior to infection the DMEM was replaced by OptiMem media (Invitrogen, Carlsbad,
CA) supplemented with 0.01 % FBS, 0.3 % BSA, 100 U/mL Penicillin, 100 µg/mL
Streptomycin, and 100 µg/mL CaCl2. For infection, the cell culture medium was removed,
and replaced with 50 µL of a biopolymer solution (ECM, mucin, BSA, or dextran). As
controls, cells were lined with DMEM, PBS or HEPES buffer (20 mM HEPES, 20 mM
NaCl, pH 7). For infection, 5 µL of virus solution was carefully added to each well (Fig. 1)
and incubated for two hours at 37 °C. This mimics the approximate time span after which a
mucus layer is renewed in vivo, owing to the synthesis of fresh mucins on the epithelial
surface and subsequent shedding of the “old” mucus layer together with trapped particles. In
our in vitro setup, the virus particles are allowed to translocate through the biopolymer
solution. This process will be driven by a combination of diffusion, turbulences created by
adding a drop of virus solution onto the biopolymer layer, and thermal convection effects.
After this incubation step, the cells were rinsed three times with 150 µL PBS. This washing
step removes the biopolymer solution together with any viruses that have not yet attached to
the cell monolayer. Then, 150 µL cell culture medium was applied and the cells were
cultured for 16 hrs (for MDCK-SIAT1-CMV-PB1) or for two more days (for HeLa and
A549), respectively, to allow for expression of GFP. For FACS analysis, the adherent cells
were harvested by trypsinization and analyzed using a LSRII flow cytometer (BD
Biosciences, San Jose, CA) or an Accuri C6 flow cytometer (Accuri Cytometers, Cambs,
UK). Uninfected control cells were used to define the base-line autofluorescence of each cell
batch. Thresholds in the analysis software (FACSDiva version 6.1.2, BD Biosciences, San
Jose, CA, or CFLow Plus, Accuri Cytometers, Cambs, UK) were chosen in such a way that
0.1 % of the control cells were counted as GFP-positive. Relatively high viral doses were
used to minimize assay variability we sometimes observed with multiplicities of infection
below 1. All experiments were performed in triplicates.
Cell toxicity assay
For assessing putative cytotoxic effects of mucins, cells were incubated with a 1 % (w/v) pH
7 mucin solution for 2 hrs, followed by washing with PBS. The cells were then incubated
with culture medium for 48 hrs. Then, the percentage of viable cells was determined using a
live/dead kit for mammalian cells (Invitrogen, Carlsbad, CA). In brief, cells were stained
with two dyes, calcein and Ethidium homodimer-1, which emit green and red fluorescence,
respectively. Cells that emit green fluorescence only are considered viable, whereas red
fluorescence is a marker for cytotoxic effects. 2 µM calcein and 2 µM Ethidium
homodimer-1 were suspended in the appropriate cell media and incubated with the cells for
20 min. Images were acquired on an Axio Observer microscope (Zeiss, Oberkochen,
Germany) with an EC-Plan Neofluar 10× 0.3 NA lens (Zeiss). Cell counts were performed
with the image analysis software ImageJ using a cell count plug-in.
Single particle tracking
For single particle tracking experiments, mucins (or dextran, or BSA) were hydrated as
described before. Fluorescently labeled HPV-16 particles were added to each biopolymer
solution, and ~30 µL of the virus/biopolymer solution was placed into an open 10 mm ×10
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mm square of vacuum grease which has been deposited onto a glass slide. This custom made
sample chamber was then sealed with a cover slip. Brownian motion of virus particles was
followed at room temperature on an Axio Observer microscope (Zeiss, Oberkochen,
Germany) with an EC Plan 40× 0.75 NA PH2 objective (Zeiss) using fluorescence
microscopy. Movies were acquired with a digital camera (ORCA-R2, C10600; Hamamatsu,
Hamamatsu City, Japan) at 10 frames/s and processed with the software OpenBox 18. For
diffusing virus particles it is highly difficult to obtain coherent trajectories r(t) = (x(t), y(t))
due to the weak contrast within the biopolymer solutions and the high virus mobility in
certain samples. Thus, the calculation of a full MSD curve, MSD(τ) = Σ [r(iΔt + τ) –
r(iΔt)]2, as typically applied to single particle tracking data is not feasible here. Instead,
from our movies we measured the squared distance δ2 = [r(t0+1s)- r(t0)]2 a given virus
particle travels by diffusion within 1 s of observation time – corresponding to 10 frames, i.e.
a time span that most of the virus particles can be followed coherently. We then calculated
the average <δ2> by pooling measurements from each sample, i.e. data for up to 50 different
virus particles and different starting time points t0. This yields a quantity that represents the
mean square displacement of the particle ensemble for a lag time of τ= 1s, <δ2> = MSD(1s).
It should be noted that, due to the limited statistics, this quantity cannot be used to determine
an accurate diffusion coefficient. It gives, however, a reasonable measure for comparing the
diffusion behavior of the VLPs in different microenvironments.
Viscosity measurements
The dynamic viscosity of the biopolymer solutions was measured with a stress controlled
rheometer (AR-G2, TA instruments, New Castle, USA) with a 40 mm cone-plate geometry
(2° cone angle) and 56 µm truncation distance. Approximately 500 µL of a biopolymer
solution was loaded onto the rheometer, subjected to a shear rate ramp in the range of 100/s
– 1000/s and the viscosities measured in this shear rate range were averaged.
Results
Hydrogels can protect cells from viral infection by trapping the viruses in the biopolymer
matrix
For initial experiments we used reporter pseudovirions based on HPV-16, an HPV type that
causes a majority of cases of cancer of the uterine cervix 19. As targets for HPV-16 infection
we chose HeLa cells, which originate from human cervical tumor tissue. In vivo, prior to
infection of the target cells, HPV-16 attaches to the basal lamina, a complex multi-
component hydrogel that supports the basal cells of the cervical epithelium 20. This
attachment process requires binding interactions between the HPV-16 capsid proteins and
the glycosaminoglycan heparan sulfate, which is one of the main components of the basal
lamina 21.
Indeed, we were able reproduce this adsorption of the virus in vitro by using a basal lamina
hydrogel (here referred to as extracellular matrix (ECM), see Materials). This hydrogel is a
complex mixture of the biopolymers collagen IV, laminin and heparan sulfate. In the
concentration regime used here, the ECM hydrogel has a mesh size on the order of a few
microns 22. Previous experiments have shown that particles much smaller than this mesh
size can be efficiently immobilized in the ECM biopolymer matrix. This immobilization
effect is, in part, established by the heparan sulfate glycosaminoglycan and due to
electrostatic binding interactions between the diffusing particles and the hydrogel
biopolymers 22.
Here, we find that an 0.25 % ECM hydrogel also suppresses the diffusive motion of HPV-16
pseudovirions (Fig. 2A), and we measured a very low diffusion coefficient of DHPV,ECM =
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(8 ± 2)×10−4 µm2/s. This value is ~10,000 times smaller than the corresponding value for
pseudovirion diffusion in buffer control conditions which we calculated to be DHPV,water =
9.6 µm2/s using the Stokes-Einstein relation, D(R ) = kBT/(6 π η R). There, kBT denotes the
thermal energy, η the viscosity of water and R the radius of the HPV-16 virus particle.
We then hypothesized that a hydrogel, which can trap virus particles inside the biopolymer
matrix, should also be able to protect underlying cells from viral infection. To test this
hypothesis, we lined a HeLa monolayer with either DMEM or with an ECM hydrogel and
then exposed the culture to HPV-16 pseudoviruses (Fig. 1 and methods). Indeed, a 0.25 %
(w/v) ECM gel reduced the percentage of infected HeLa cells about 6-fold compared to the
positive control (Fig. 2B). The shielding efficiency of ECM becomes stronger at higher
biopolymer concentrations where the HPV-16 infection rate is reduced to only a few
percent. Together, these data demonstrate that ECM hydrogels have the capacity to
effectively prevent viruses from infecting underlying cells, and that this is achieved by
trapping the viruses in the biopolymer matrix.
Reconstituted mucin solutions do not compromise the viability of HeLa cells
In the remainder of this article we aim at testing whether purified porcine gastric mucins can
also serve as an anti-viral infection barrier. However, before assessing the impact of porcine
gastric mucins on the diffusion behavior and infectivity of HPV-16, we verified that
reconstituted mucin solutions are non-toxic for HeLa cells (see Methods). We found that
HeLa cells exposed to the mucin solution showed a viability that was comparable to cultures
exposed to the HEPES buffer control (Table 1). Similar results were obtained for
commercial porcine gastric mucins purchased from Sigma Aldrich. However, commercial
mucins obtained from another vendor (NBC Biologicals, Huntingdon, UK) appear to induce
strong cytotoxic effects as the corresponding percentage of viable cells was very low. We
conclude that our manually purified mucin solutions constitute a biocompatible material that
does not compromise the viability of HeLa cells.
Mucin solutions retard HPV-16 diffusion
If porcine gastric mucins are supposed to act as an infection barrier towards HPV-16 viruses,
then trapping of virus particles inside the mucin matrix would be a possible mechanism to
achieve this goal, similar to what we observed for ECM hydrogels. Thus, we next analyzed
the diffusion behavior of individual fluorescently labeled HPV-16 VLPs in mucin solutions
using single particle tracking microscopy (Fig. 3A and Methods). In HEPES buffer, HPV-16
diffused rapidly and it was difficult to follow a given VLP for an extended time period as
most of the virus particles left the focal plane during the observation time. In contrast, in a 1
% mucin solution, the diffusive motion of HPV-16 VLPs was significantly suppressed. As
depicted in Fig. 3A, this retardation of HPV-16 diffusion is even more pronounced when the
pH level of the mucin solution is lowered from pH 7 to pH 3. At the acidic pH, where the
mucin biopolymers form a hydrogel 11b, the VLPs appeared to be completely immobilized.
Importantly, this lockdown of virion mobility appeared to be a global effect since we did not
detect any mobile VLPs in the pH 3 sample.
To better quantify the observed differences in the VLP diffusion behavior, we determined
the mean square displacement for an ensemble of up to 50 virus particles per condition at a
lag time of 1 s (see Methods). As depicted in Fig. 3B, this ensemble quantity reflected the
pronounced differences observed in the trajectories of single virus particles. In other words,
mucin solutions were able to efficiently trap the VLPs both at neutral and acidic pH. This
suggests that mucin solutions should also be able to employ this trapping of HPV-16 virus
particles to act as an infection shield in our in vitro infection assay.
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Mucin solutions pose a barrier towards HPV-16 infection
In the next step, we evaluated the performance of porcine gastric mucins as a barrier towards
viral infection. When HEPES buffer is used as the sole protective layer, more than 65 % of
the cells were infected (Fig. 4A). In contrast, when the cells were covered with a 1 % (w/v)
mucin solution prior to virus inoculation, the proportion of infected cells was decreased to
~6 %. The shielding efficiency of the mucin solution depended on the mucin concentration
used (Fig. 4A), confirming previous findings that the permeability of mucin solutions can be
regulated by the mucin concentration 23, in analogy to native mucus 24. This demonstrates
that purified mucins can indeed pose an efficient barrier towards HPV-16 infection.
Interestingly, commercial porcine gastric mucins obtained from Sigma Aldrich are less
efficient in reducing HPV-16 infection when used at a similar concentration as our manually
purified mucins (Table 1). Similarly, also particle diffusion experiments have shown that
commercially purified mucins do not establish the same diffusion control as native intestinal
mucus 25. Our findings suggest that the detailed mucin purification protocol and mucin
biochemistry might be important for the performance of mucins as a barrier towards viral
infection.
Mucin solutions form more efficient diffusion and infection barriers than BSA or dextran
solutions
Can any solution of macromolecules protect cells from viral infections or are certain
biopolymer properties required to achieve this effect? To tackle this question, we compared
our results obtained for 1 % (w/v) mucin solutions to two other biopolymer solutions: a
bovine serum albumin (BSA, MW ~ 66 kDA) solution and a dextran solution (MW ~ 2
MDa), which were both prepared at the same concentration as the mucin solution, i.e. at 1 %
(w/v) (Fig. 5A). When used as a shielding layer in our in vitro infection assay, BSA did not
cause a major reduction in the infectivity of HPV-16, and dextran was only moderately
inhibitory (Fig. 5B). Moreover, neither the BSA solution nor the dextran solution appeared
to significantly inhibit HPV-16 diffusion (Fig. 3A and B). This suggests that the inhibitory
effect of dextran observed in Fig. 5B is not simply due to a reduction of virus diffusion, but
rather that dextran may modestly inhibit a subsequent step in the infection process. These
results suggest that unique chemical/physical properties of the mucin biopolymer may be
needed for efficient virus trapping and infection blocking.
Mucin solutions also pose a barrier towards influenza and MCV infection
We next investigated whether the shielding effect of mucin solutions is specific for HPV-16
or whether mucins can prevent other small viruses from infecting epithelial cells as well. To
address this question we repeated the in vitro infection experiments described before, but
this time using influenza viruses (100 nm). Influenza A belongs to the virus family
Orthomyxoviridae and infects the epithelia in the respiratory tract of humans. The
introduction of new influenza subtypes into the human population can cause pandemics,
including the deadly 1918 pandemic (which is estimated to have killed over 40 million
people worldwide 26) and more recently the 2009 swine-origin H1N1 pandemic 27. As
targets for infection with the A/WSN/33 (H1N1) strain of influenza used in this study, we
chose modified canine kidney cells (MDCK-SIAT1- PB1, see Methods). The viability of
this cells type was also unaffected by our 1 % (w/v) mucin solution (Table 1).
With our in vitro infection assay, we found a similar ability of mucins to block influenza
infection as observed for HPV-16 pseudoviruses (Fig. 4B). A comparable dependency of
this infection barrier efficiency on the mucin concentration was obtained when HEPES or
PBS was used as a buffer for mucin reconstitution, respectively (Fig. 4B). Furthermore, the
inhibitory profiles of BSA, dextran and mucin towards influenza infection resembled those
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obtained for the HPV/HeLa cell pair, with mucins being much more efficient than BSA or
dextran (Fig. 5C).
As a third virus species, we also investigated the Merkel cell polyomavirus (MCV, ~50 nm),
which is believed to infect both the skin and the oral mucosa 28. MCV is a member of the
viral family Polyomaviridae and is thought to trigger Merkel cell carcinoma, an aggressive
form of skin cancer. MCV pseudoviruses can successfully transduce A549 cells, a cell line
established from a human lung epithelial tumor. With this virus/cell pair, we observed the
same trend in the protective ability of BSA, dextran, and mucin solutions as for the HPV-16/
HeLa and the influenza/MDCK combinations (Fig. 5D). In agreement with our previous
findings on HeLa and MDCK cells, we also observed that the viability of A549 lung cells
was not compromised by exposure to a 1 % (w/v) mucin solution (Table 1) underscoring the
biocompatibility of our purified mucin biopolymers.
Together, these data demonstrate that the mucin biopolymer matrix imposes an efficient
infection barrier not only towards HPV-16 but also towards influenza and MCV.
High NaCl concentrations increase the barrier function of mucins
Rinsing the nose or the oral cavity with saline solutions is a traditional household remedy for
the common cold. Thus, in a final step, we asked how different concentrations of sodium
chloride in the mucin hydration buffer would affect the inhibitory activities of mucin
solutions towards viral infection. For this set of experiments we chose the influenza/MDCK
cell pair, as only MDCK cells showed strong enough adhesion to allow us performing our in
vitro infection assay in the presence of high NaCl concentrations.
When mucins were hydrated in low salt HEPES buffer (20 mM NaCl), the concentration
dependent inhibitory activity of mucins was comparable to the situation when PBS (140 mM
NaCl and minor amounts of divalent ions) was used for mucin hydration (Fig. 4B).
Accordingly, also HEPES buffer containing 150 mM NaCl returned comparable results
when used as a hydration medium for 0.25 % (w/v) and 1 % (w/v) mucin solutions (Fig. 6A
and B). However, when the NaCl concentration of the HEPES buffer was increased to 300
mM (Fig. 6A), we detected a significant enhancement of the influenza inhibition efficiency
provided by a 1 % (w/v) mucin solution. This effect is not due to an altered base-line
infectivity or reduced virus stability, as the control samples were unaffected by the change in
the ionic strength of the mucin hydration buffer. A similar trend, albeit much stronger, was
observed when the NaCl concentration was varied in a 0.25 % (w/v) mucin solution. At this
low mucin concentration, the inhibitory activity of the mucin solution was drastically
enhanced by raising the NaCl concentration (Fig. 6B). Surprisingly, at 500 mM NaCl, the
low concentration mucin solution was as efficient in reducing influenza infectivity as the 1
% (w/v) mucin solutions discussed before.
These results demonstrate that the ability of mucin solutions to act as an anti-viral infection
shield can be strengthened by high NaCl concentrations.
Discussion
Our data reveal that purified porcine gastric mucins can efficiently shield an underlying cell
monolayer from infection by viruses as small as 50 nm in diameter. This effect can be
achieved with mucin concentrations as low as 0.25 – 1 % (w/v) which is 4–5fold lower than
the mucin concentrations found in native mucus 29. Data obtained at the single particle level
suggest that the barrier function of mucin solutions is achieved in part by suppressing the
mobility of virus particles and trapping them inside the biopolymer matrix. Previous studies
on virus diffusion in native mucus have suggested that this immobilization effect is based on
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adhesive interactions with certain mucus components, and a similar mechanism – in addition
to geometric hindrance effects – might also be responsible for the virus trapping described
here. However, owing to the lower mucin concentration, the mesh size of our reconstituted
mucin system should be larger than the literature value of 300 nm reported for native
cervical mucus and thus significantly larger than the diameter of the viruses studied here.
This suggests that geometric hindrance is not likely to be the main mechanism by which
mucin solutions trap virus particles.
The anti-viral activity of mucins is still observable when the mucin layer is removed from
the cells by washing prior to virus inoculation (data not shown). It is possible that mucin
polymers remain on the cellular surface after the washing step, and that these could act as a
passivation agent by blocking the cell receptors required for virus binding thus preventing
successful cell infection. Such a cell membrane passivation mechanism might also explain
the modest inhibitory effect of dextran and even BSA mentioned earlier and could constitute
a second anti-viral defensive mechanism provided by mucins besides virus trapping.
Alternatively, this could indicate that, indeed, the interaction with mucins affects cell
physiology, perhaps by modulating the cytoskeleton, or by other, entirely unrelated cellular
mechanisms that render cells more resistant toward viral infection.
We have shown that the trapping of HPV-16 inside the mucin matrix is more efficient at low
pH. This agrees with previous findings on particle diffusion and particle translocation
experiments in reconstituted mucin solutions 23, 30 and underlines the possibility to tune the
permeability of this biopolymer based diffusion barrier by pH. We emphasize that our single
particle tracking assay might still underestimate the virus trapping effect established by
mucins: the residual mobility observed for HPV viruses in mucin solutions could represent
thermal undulations of the mucin biopolymers to which the virus particles are bound, rather
than a true local diffusion of the virus particles.
Which components of reconstituted mucin solutions could be responsible for trapping virus
particles inside the biopolymer matrix? One commonality of the viruses studied here is their
interaction with sugar groups during the infection process. HPV-16, for example, targets
negatively charged heparan sulfate chains in the ECM or on the cell surface. MCV appears
to use heparan sulfate and sialyated glycans as receptors 17, 31. Influenza attaches to cells via
binding of the hemagglutinin protein to sialic acid moieties on the host cell. Mucins contain
polyanionic sugars including sialic acid 1b, which may serve as decoys for the various
receptors utilized by the three virus families we studied here. It is interesting to note that
commensal and pathogenic microbes appear to specifically target such sugar moieties when
they are trying to weaken the native mucus barrier by enzymatic degradation 32, and that the
influenza neuraminidase protein can cleave sialic acid moieties 33. This supports the notion
that those sugar moieties indeed play an important role in the defense mechanism of mucins
towards pathogens.
Whereas the detailed mechanistic and molecular principles that establish the adhesive effects
between viruses and mucins are still to be deciphered, the adsorption of the virus particles to
mucins could, at least in part, be due to relatively non-specific electrostatic interactions with
either the sugar moieties or with the protein backbone of the mucin biopolymers (Fig. 7).
Electrostatic interactions have already been suggested to contribute to the trapping of
polystyrene particles inside reconstituted mucin solutions 23. However, other physical
interactions such as van-der-Waals forces or hydrogen bonds could also cause trapping of
viruses inside the mucin matrix. Indeed, our finding that high NaCl concentrations
strengthen the barrier function of mucin solutions demonstrates that electrostatic binding
interactions are not sufficient to explain the barrier properties of mucins towards virus
particles. At high ionic strength, the electrostatic interactions between the virus capsids and
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the mucin biopolymers should be sufficiently weakened by Debye screening. Thus, if
binding of influenza viruses by mucins were based on electrostatic interactions only, then
high ion concentrations would be expected to reduce the barrier function of mucins towards
influenza rather than strengthen it.
In native mucus such as saliva, certain ions such as Ca2+ increase the macroscopic viscosity
of the hydrogel and retard the diffusion of tracer particles 34. The viscosity of our mucin
solutions, however, is reduced by (12 ± 7) % at 500 mM NaCl compared to low salt
conditions. Therefore, an altered viscosity of our mucin solution cannot account for the
enhanced influenza inhibition of mucin solutions at high NaCl concentrations. Instead, we
speculate that multiple low-affinity bonds (based on e.g. polar and/or hydrophobic
interactions) between the mucin sugar groups and the virus capsids might be responsible for
the trapping of the virus particles. Which combination of physical forces regulates these
binding interactions and how they depend on the detailed buffer milieu is a complex
question that will need to be addressed in detail in future experiments.
Once the detailed biochemical motifs in the mucin biopolymer are determined that are
responsible for binding virus particles, then mucin biopolymers might also serve as a good
role model for the de novo synthesis of engineered biopolymer materials, which trap virus
particles and thus act as an artificial shielding layer towards viral infection. Indeed, a recent
study employs mucin-like polysaccharide motifs in engineered polymers to trap HIV viruses
in the polymer matrix35. The in vitro infection assay presented here provides a suitable
platform for the screening of such engineered hydrogels to evaluate both their
biocompatibility and their efficiency as an infection barrier in one convenient format.
So far, viral translocation through mucus has been studied essentially by two methods,
namely single particle tracking 3 and fluorescence recovery after photobleaching 36. Here,
we present a third approach, an in vitro infection assay that measures bulk translocation of
virus particles through mucin solutions, or other biopolymer materials. This assay has
several advantages compared to single particle tracking studies. First, it does not require
fluorescence labeling of the virus capsid. Such a labelling is mandatory for optical tracking
experiments with such small particles but might introduce artifacts if the label enhances or
reduces adhesive interactions with the biopolymers. Second, the assay measures the bulk
permeability of a biopolymer solution or a hydrogel by analyzing the infection status of a
whole underlying cell layer. Thus, the infection assay directly takes into account putative
heterogeneities in the hydrogel architecture, which otherwise can require numerous time-
consuming single particle measurements for their detection.
Conclusion
Due to their antiviral activity, biocompatibility and availability in relatively large quantities,
isolated porcine gastric mucins might be suitable candidates for supplements in personal
hygiene products such as mouth rinse or tooth paste. They might also be good additives for
wound treatment ointments or for genital lubricants, where they could help protecting our
inner or outer body surfaces from viral infection. Porcine gastric mucins can be purified in
bulk, and they are already used as components for artificial saliva. Their ability to block
human pathogenic viruses might not be limited to HPV-16, MCV, and influenza but could
potentially also apply to other viruses such as HIV, HSV, and Hepatitis B or C. Thus we
envision porcine gastric mucins to be promising antiviral components for future biomedical
applications.
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Figure 1.
Schematic representation of the in vitro infection assay used in this study. (A) A monolayer
of suitable target cells is lined with a biopolymer solution which is then exposed to a small
drop of a virus solution. (B) The cells are incubated with the biopolymer solution and the
viruses for 2 h. During this time the viruses may spread through the biopolymer solution and
infect the underlying cells. (C) The biopolymers and remaining viruses are removed by
washing with PBS and the cells are incubated for 48 h. All viruses used in this study carry a
gene encoding GFP, allowing for distinguishing infected cells (GFP-positive) from
uninfected cells (GFP-negative) by flow cytometry.
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Figure 2.
Basal lamina (ECM) hydrogels trap HPV-16 viruses and act as an infection barrier. (A)
Trajectories of ~20 s duration for HPV-16 VLPs in the absence of biopolymers (orange) and
in 0.25 % (w/v) ECM (red). (B) Percentage of HPV-16-infected HeLa cells using ECM
hydrogels at increasing biopolymer concentrations as an infection shield. Error bars denote
the error of the mean from three independent experiments.
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Figure 3.
The diffusive motion of HPV-16 VLPs depends on the microenvironment. (A) Trajectories
of 20 s duration for single HPV-16 VLPs in different biopolymer solutions. (B) Averaged
square displacement of HPV-16 VLPs calculated for a diffusion time of 1 s (see Methods).
HPV-16 diffusion is significantly reduced in 1 % (w/v) mucin at pH 7 and massively
suppressed in 1 % (w/v) mucin at pH 3. The error bars denote the error of the mean. The
number of viral particles analyzed was N=13 for HEPES buffer, N=22 for BSA, N=26 for
dextran, N=54 for mucin pH 7 and N=51 for mucin pH 3.
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Figure 4.
The efficiency of mucin solutions as a shielding layer towards viral infection depends on the
mucin concentration. Suitable cells are employed as an infection target, and the percentage
of infected (= GFP-positive) cells is determined by flow cytometry. With increasing mucin
concentration, the percentage of HeLa cells infected by HPV-16 (A) and the percentage of
MDCK cells infected by influenza (B) is decreased from ~70–80 % to ~6 %. A similar trend
is obtained if PBS is used as a mucin hydration buffer instead of HEPES (B). Error bars
denote the error of the mean from three independent experiments.
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Figure 5.
Mucin solutions form more efficient infection shields than BSA or dextran solutions. (A)
Pictograms of epithelial cells that are lined with a BSA, dextran or mucin solution. The
percentages of infected cells in the presence of these different biopolymers are depicted for
the HPV-16/HeLa pair in (B), for the influenza/MDCK pair in (C), and for the MCV/A549
pair in (D). As a reference, buffer w/o biopolymers is used. Error bars denote the error of the
mean as obtained from three independent experiments.
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Figure 6.
The efficiency of mucin solutions to block influenza infection depends on the NaCl
concentration of the mucin reconstitution buffer. The percentage of MDCK cells infected by
influenza decreases with increasing NaCl concentrations both for 1 % (w/v) mucin solutions
(A) and for 0.25 % (w/v) mucin solutions (B). In the latter case, the enhancement in the
protective ability of the mucin solution is much more pronounced. For both data sets, the
base-line infection rate of MDCK cells remains unaffected by the amount of NaCl added.
Lieleg et al. Page 19
Biomacromolecules. Author manuscript; available in PMC 2013 June 11.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 7.
Schematic representation of a possible mechanism that might allow mucin solutions to act as
a barrier towards viral infection. Mucin biopolymers may offer competing binding sites that
trap the viruses inside the biopolymer matrix (see main text for discussion). As a
consequence, those viruses are prevented from reaching the epithelial surface.
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Table 1
Survival of HeLa, A549 and MDCK-SIAT-1-CMV-PB1 cells after exposure to different mucin solutions and
percentage of GFP-positive cells after HPV-16 inoculation in presence of mucins. ++ := > 85 %. − − := < 5 %.
N.D.: not determined.
buffer 1 % mucin 1 % Sigma mucin 1 % NBS mucin
viable HeLa cells ++ ++ ++ − −
viable A549 cells ++ ++ N.D. N.D.
viable MDCK cells ++ ++ N.D. N.D.
GFP-positive HeLa cells after HPV-16 inoculation (89.5 ± 0.1) % (3.5 ± 1.5) % (15.5 ± 0.7) % N.D.
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